Text Size

Treatment Program for Anemia in AIDS Patients

This study has been completed.
Sponsor:
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00002022
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: February 1991
History of Changes
  Purpose

The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.


Condition Intervention
HIV Infections
Cytopenias
 Drug: Epoetin alfa

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Treatment Program for Anemia in AIDS Patients

Resource links provided by NLM:

MedlinePlus related topics: Anemia HIV/AIDS
U.S. FDA Resources

Further study details as provided by NIH AIDS Clinical Trials Information Service:

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

  • Life expectancy < 3 months.
  • = or < grade 4 performance score.
  • AIDS-related dementia.
  • Uncontrolled hypertension.
  • Acute symptomatic opportunistic infection or other AIDS-defining illness.

Patients with the following are excluded:

  • Life expectancy < 3 months.
  • = or < grade 4 performance score.
  • AIDS-related dementia.
  • Uncontrolled hypertension.
  • Acute symptomatic opportunistic infection or other AIDS-defining illness.

Patients must have:

  • A clinical diagnosis of AIDS.
  • Hematocrit < 30 percent.
  • Endogenous serum erythropoietin level = or < 500 U/ml.
  • A life expectancy = or > 3 months.
  • > Grade 4 performance score.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002022

Locations
United States, New Jersey
R W Johnson Pharmaceutical Research Institute
Raritan, New Jersey, United States, 088690602
Sponsors and Collaborators
R W Johnson Pharmaceutical Research Institute
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00002022     History of Changes
Other Study ID Numbers: 004G, I88-083
Study First Received: November 2, 1999
Last Updated: June 23, 2005
Health Authority: United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:
Recombinant Proteins
Drugs, Investigational
Erythropoietin
 Acquired Immunodeficiency Syndrome
Anemia
Zidovudine

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Anemia
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
 Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Hematologic Diseases
Epoetin Alfa
Hematinics
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 16, 2013